Outcome Study to Evaluate the Role of Klaricid XL (Clarithromycin Modified Release) in the Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) and Its Impact on Quality of Life Measured by St. George's Respiratory Questionnaire (SGRQ).

Trial Profile

Outcome Study to Evaluate the Role of Klaricid XL (Clarithromycin Modified Release) in the Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) and Its Impact on Quality of Life Measured by St. George's Respiratory Questionnaire (SGRQ).

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2013

At a glance

  • Drugs Clarithromycin (Primary)
  • Indications Acute exacerbations of chronic bronchitis; Bacterial infections
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 29 Jan 2013 Official title and primary endpoint amended as reported by ClinicalTrials.gov.
    • 01 Feb 2012 Actual patient number is 220 according to ClinicalTrials.gov.
    • 01 Feb 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top